,,ii  #aaeth ,,congress  #b;d ,session  
,s4 #bhhe  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,may #ag1 #bjah
 ,ms4 ,smith introduced the following   
bill2 which was read twice and referred 
to the ,committee on ,banking1 ,housing1
 and ,urban ,affairs  ,a ,,bill  ,to    
amend the ,securities ,exchange ,act of 
#aicd to require additional disclosure  
for pharmaceutical companies4  #a4      
,short title  ,this ,act may be cited as
 the ,disclosing ,pharmaceutical        
,company ,windfall ,profits ,act of     
#bjah4  #b4 ,additional disclosure for  
pharmaceutical companies ,section #ac of
 the ,securities ,exchange ,act of #aicd
 7#ae ,u4,s4,c4 #ghm7 is amended by     
adding at the end the following3  7s7   
,additional disclosure for              
pharmaceutical companies  7#a7 ,in      
general ,each issuer required to file an
 annual or quarterly report under       
subsection 7a7 shall disclose in that   
report the information required by      
paragraph 7#b7 if1 during the period    

covered by the report1 the issuer or any
 affiliate of the issuer is a drug      
manufacturer4  7#b7 ,information        
required ,if an issuer or an affiliate  
of the issuer is required to make a     
disclosure pursuant to paragraph 7#a71  
the disclosure shall include--  7,a7 a  
country-by-country report2  7,b7 a      
description of any change in dividend or
 change in share repurchase plan after  
,november #b1 #bjag1 and the total value
 of such change2  7,c7 bonuses or other 
changes in compensation of officers or  
directors after ,november #b1 #bjag1 and
 the total value and percentage changes 
in comparison to the prior year2  7,d7  
the total value of the research and     
experimentation tax credit 7pursuant to 
section #da of the ,internal ,revenue   
,code of #aihf7 claimed by the issuer or
 any affiliate for the preceding tax    
year2  7,e7 the change in spending on   
research and development of prescription
 drugs1 including an estimate of total  
value of investment in research and     

development and the total value of any  
change in research and development for  
which the change was principally the    
result of ,public ,law #aae-ig 7#aca    
,stat4 #bjed72  7,f7 the total amount   
of-- 7i7 deferred foreign income subject
 to mandatory inclusion pursuant to     
section #ife7;a7 of the ,internal       
,revenue ,code of #aihf2 and  7ii7      
deductions allowable under section      
#ife7;c7 of such ,code1 including the   
amount of such deductions attributable  
to the #h percent rate equivalent       
percentage and the amount attributable  
to the #ae4e percent rate equivalent    
percentage2  7,g7 amounts described in  
section #afb7;e7 of the ,internal       
,revenue ,code of #aihf2 and  7,h7 any  
other material actions by the issuer for
 which the action was principally the   
result of ,public ,law #aae-ig 7#aca    
,stat4 #bjed74  7#c7 ,foreign           
subsidiaries ,for each foreign          
subsidiary in the country-by-country    
report1 the report required by paragraph

 7#a7 shall be grouped by resident      
jurisdiction 7including a group for     
subsidiaries resident nowhere71 the tax 
jurisdiction 7if different71 and main   
business activity4  7#d7 ,definitions   
,in this subsection3 7,a7               
,country-by-country report ,the term    
country-by-country report means         
information on a country-by-country     
basis during the covered period for each
 tax jurisdiction1 aggregated from all  
subsidiaries residing in that           
jurisdiction1 consisting of--  7i7      
revenues from unrelated parties1 related
 parties1 and in total2  7ii7 profit or 
loss before taxes2  7iii7 income tax    
accrued for the current year2  7iv7     
income tax paid 7on a cash basis72  7v7 
stated capital2  7vi7 accumulated       
earnings2  7vii7 number of employees2   
7viii7 tangible assets other than cash  
or cash equivalents2 and  7ix7 such     
other financial information as the      
,commission may determine is necessary  
or appropriate in the public interest or

 for the protection of investors4  7,b7 
,drug manufacturer ,the term drug       
manufacturer means the person that holds
 the application for a drug approved    
under section #eje of the ,federal      
,food1 ,drug1 and ,cosmetic ,act 7#ba   
,u4,s4,c4 #cee7 or the license issued   
under section #cea of the ,public       
,health ,service ,act 7#db ,u4,s4,c4    
#bfb74  4